Will Rising Costs Hurt Elevance's Q3 Earnings Despite Higher Premiums?

Elevance Health (ELV) is anticipated to report a 40.6% year-over-year decline in Q3 2025 EPS to $4.97, despite projected revenue growth of 10.7% to $49.5 billion, driven by higher premiums and product revenues. However, elevated expenses, including a 9% increase in total expenses and a significant 45.5% decrease in the Health Benefits segment's operating income, are expected to pressure profit margins, leading to an uncertain earnings beat outlook and a Zacks Rank #4 (Sell).

Analysis

Elevance Health (ELV) is projected to report a significant 40.6% year-over-year decline in Q3 2025 EPS to $4.97, despite an anticipated 10.7% increase in revenues to $49.5 billion. This divergence highlights severe margin compression, with the Zacks Consensus Estimate for 2025 EPS also indicating a 9.3% decrease. The company's Zacks Rank #4 (Sell) and an uncertain earnings beat prediction model further underscore potential underperformance.

Revenue growth is expected to be driven by an 11.5% increase in premiums and a 7.7% rise in product revenues. The Carelon brand's operating income is projected to increase by 4.1% year-over-year, supported by CarelonRx and strategic buyouts in home health and pharmacy services. Commercial Individual memberships are also forecast to grow by 1.7%.

However, profitability is severely impacted by elevated expenses, including a projected 9% year-over-year jump in total expenses. The benefit expense ratio is estimated at 91.6, up from 89.5, indicating higher costs of care. Critically, the Health Benefits segment's operating income is expected to decrease by a substantial 45.5%, exacerbated by declining Medicaid memberships which are constraining premium growth.

Key Decisions for Investors

• Investors should exercise caution regarding ELV given the projected significant EPS decline despite revenue growth, indicating severe margin pressure.
• Monitor the upcoming Q3 earnings report closely for details on expense management, particularly within the Health Benefits segment, and the impact of Medicaid membership trends.
• Given the Zacks Rank #4 (Sell) and uncertain earnings beat prediction, re-evaluate current positions and consider potential downside risks or alternative investments in the medical space with stronger earnings outlooks.